ArticleNeurology and therapy2023

Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.

Jason Aldred et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.